Electra Therapeutics Raises $350m in Upsized Nasdaq IPO

Electra Therapeutics has raised $350 million through an upsized initial public offering, pricing its shares at $15 each. The clinical-stage biotech company sold 23.3 million shares in the transaction, which was fully primary, meaning all proceeds flow directly to the company’s balance sheet rather than existing holders.

Despite the successful capital raise, the stock experienced a significant drop on its first day of trading on the Nasdaq Global Select Market. Shares closed at $13.25, representing a decline of nearly 12% from the IPO price, according to reporting by The Pharma Letter.

Offering size and valuation details

The final deal size exceeded the company’s initial proposal of 21.7 million shares. This upsizing allowed Electra to achieve a fully diluted market value of approximately $1 billion at the time of pricing. The company had originally targeted a price range of $14 to $16 per share before settling on the $15 mark.

Market reaction to debut

Investors traded the shares at a discount to the offering price during the initial session. The closing price of $13.25 indicates a lack of immediate premium demand despite the company’s backing by OrbiMed. The price movement reflects a cautious stance on the valuation of this clinical-stage asset.

Capital allocation and investor base

Because the offering consisted entirely of new shares issued by Electra, the $350 million in proceeds will be used to fund its ongoing operations and pipeline development. The transaction does not involve the sale of secondary shares by current investors, preserving the existing ownership structure while injecting fresh capital into the business.